<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="63233">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02282722</url>
  </required_header>
  <id_info>
    <org_study_id>15-143</org_study_id>
    <secondary_id>CE-1304-6517</secondary_id>
    <secondary_id>1UG1CA189823-01</secondary_id>
    <nct_id>NCT02282722</nct_id>
  </id_info>
  <brief_title>Improving Informed Consent for Palliative Chemotherapy</brief_title>
  <official_title>Improving Informed Consent for Palliative Chemotherapy: Development of a Regimen-Specific Multi-Media Informed Consent Library To Promote Patient-Centered Decision-Making About Treatment of Advanced Gastrointestinal Cancers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Dana-Farber Cancer Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Patient-Centered Outcomes Research Institute</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Alliance for Clinical Trials in Oncology</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Dana-Farber Cancer Institute</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Patients are routinely asked to sign an &quot;informed consent&quot; document prior to starting
      chemotherapy, indicating they understand the risks and benefits of treatment. Although this
      could be a strategic moment to equip patients with information they need to make truly
      informed medical decisions, many patients and caregivers note that these conversations are
      less useful than they could be. The informed consent process and its associated documents
      suffer several limitations: 1) risks are emphasized over benefits; 2) educational materials
      focus on individual drugs instead of regimens; 3) information is presented in written
      instead of alternative written/audiovisual format; and 4) the patient perspective is
      lacking.

      The overarching objective of this project is to develop a library of communication tools for
      the most common chemotherapy regimens used to treat metastatic colorectal cancer. Tools will
      include video clips and written documents that can be readily distributed, modified, and
      customized. This toolkit will be crafted in collaboration with oncologists and patients
      living with gastrointestinal cancer and improves upon existing resources in several ways: 1)
      balanced discussion of benefits as well as risks, 2) focus on regimens rather than drugs, 3)
      use of both written and video format, and 4) inclusion of the patient perspective (e.g.
      video clips of patients describing their experience). A panel of oncologist and patient
      stakeholders will evaluate the acceptability of the tools. The investigators will then
      conduct a randomized clinical trial to demonstrate if the informed consent toolkit improves
      the quality of informed consent for palliative chemotherapy. If effective, the tools will be
      amenable to broad dissemination via patient accessible cancer education websites and
      oncology clinics.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A substantial body of research indicates that many patients with incurable cancer harbor
      significant misconceptions about the benefits of palliative chemotherapy. This
      misunderstanding indicates pervasive deficiencies in how cancer patients are informed about
      fundamentals of their disease and treatment options.

      The root of this problem is undoubtedly complex, but likely relates to deficiencies in
      patient-doctor communication about incurable cancer. At the outset of treatment, it is
      important for oncologists to establish trust, a strong rapport, and convey hope even when
      prognosis is poor. As a result, oncologists may describe difficult information about
      prognosis and the limitations of chemotherapy in a telescopic or vague manner that makes it
      difficult for patients to understand what lies ahead. While this approach may initially
      provide solace, downstream it can impede patients' ability to make truly informed choices
      about how to allocate their limited time and energy.

      Patients are routinely asked to sign an &quot;informed consent&quot; document prior to starting
      chemotherapy, indicating they understand the risks and benefits of treatment. Although this
      could be a strategic moment to equip patients with information they need to make truly
      informed medical decisions, many patients and caregivers note that these conversations are
      less useful than they could be. The informed consent process and its associated documents
      suffer several limitations: 1) risks are emphasized over benefits; 2) educational materials
      focus on individual drugs instead of regimens; 3) information is presented in written
      instead of alternative written/audiovisual format; and 4) the patient perspective is
      lacking.

      The overarching objective of this project is to develop a library of communication tools for
      the most common chemotherapy regimens used to treat metastatic colorectal cancer. Tools will
      include video clips and written documents that can be readily distributed, modified, and
      customized. This toolkit will be crafted in collaboration with oncologists and patients
      living with gastrointestinal cancer and improves upon existing resources in several ways: 1)
      balanced discussion of benefits as well as risks, 2) focus on regimens rather than drugs, 3)
      use of both written and video format, and 4) inclusion of the patient perspective (e.g.
      video clips of patients describing their experience). A panel of oncologist and patient
      stakeholders will evaluate the acceptability of the tools. The investigators will then
      conduct a randomized clinical trial to demonstrate if the informed consent toolkit improves
      the quality of informed consent for palliative chemotherapy. If effective, the tools will be
      amenable to broad dissemination via patient accessible cancer education websites and
      oncology clinics.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>December 2013</start_date>
  <completion_date type="Anticipated">September 2017</completion_date>
  <primary_completion_date type="Anticipated">March 2017</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>No masking</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Proportion of participants at 4 months who understand the benefits of palliative chemotherapy</measure>
    <time_frame>4 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Proportion of participants with core knowledge required for informed consent</measure>
    <time_frame>4 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of participants with decisional conflict</measure>
    <time_frame>4 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of patients achieving their desired role in decision-making</measure>
    <time_frame>4 months</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">300</enrollment>
  <condition>Metastatic Colorectal Cancer</condition>
  <arm_group>
    <arm_group_label>Usual informed consent</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Study participant will receive usual, standard-of-care informed consent for chemotherapy materials.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Investigational informed consent</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Study participant will receive investigational informed consent for chemotherapy materials that were developed by the study team.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Investigational informed consent for chemotherapy</intervention_name>
    <description>Investigational informed consent materials consist of regimen-specific multimedia tools: a video plus a booklet.</description>
    <arm_group_label>Investigational informed consent</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Usual, standard-of-care informed consent for chemotherapy</intervention_name>
    <description>The enrolling site's institutional standard-of-care informed consent materials.</description>
    <arm_group_label>Usual informed consent</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Diagnosis of advanced colorectal cancer with metastasis, locally advanced pancreatic
             cancer, or metastatic pancreatic cancer.

          -  Is considering treatment with 1st line or 2nd line chemotherapy

          -  Treating oncologist has recommended consideration of one or more of the regimens for
             which we have developed informed consent materials

          -  Age â‰¥ 21

          -  English proficiency (reading and speaking)

        Exclusion Criteria:

          -  Significant delirium/dementia as judged by the treating physician

          -  Isolated liver metastases being evaluated for curative resection

        In addition, caregivers of eligible patients will also be eligible to participate in the
        caregivers assessments.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Deborah Schrag, MD MPH</last_name>
    <role>Principal Investigator</role>
    <affiliation>Dana-Farber Cancer Institute</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Deborah Schrag, MD MPH</last_name>
    <phone>617-582-8301</phone>
    <email>deb_schrag@dfci.harvard.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Andrea Enzinger, MD</last_name>
    <phone>617-582-7335</phone>
    <email>andrea_enzinger@dfci.harvard.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University of California at San Francisco</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94143</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Beth Israel Deaconess Medical Center</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02215</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Andrea Bullock, MD</last_name>
      <phone>617-667-2100</phone>
      <email>abullock@bidmc.harvard.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Dana-Farber Cancer Institute</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02215</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Deborah Schrag, MD MPH</last_name>
      <phone>617-582-8301</phone>
      <email>deb_schrag@dfci.harvard.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Dana-Farber at Milford</name>
      <address>
        <city>Milford</city>
        <state>Massachusetts</state>
        <zip>01757</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Michael Constantine, MD</last_name>
      <phone>508-488-3700</phone>
      <email>Michael_Constantine@dfci.harvard.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Dana-Farber at South Shore</name>
      <address>
        <city>South Weymouth</city>
        <state>Massachusetts</state>
        <zip>02190</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Meredith Faggen, MD</last_name>
      <phone>781-624-4800</phone>
      <email>meredith_faggen@dfci.harvar</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of North Carolina at Chapel Hill</name>
      <address>
        <city>Chapel Hill</city>
        <state>North Carolina</state>
        <zip>27599</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novant Health</name>
      <address>
        <city>Winston-Salem</city>
        <state>North Carolina</state>
        <zip>27103</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Virginia Commonwealth University</name>
      <address>
        <city>Richmond</city>
        <state>Virginia</state>
        <zip>23284</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2017</verification_date>
  <lastchanged_date>January 30, 2017</lastchanged_date>
  <firstreceived_date>October 27, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Dana-Farber Cancer Institute</investigator_affiliation>
    <investigator_full_name>Deborah Schrag, MD</investigator_full_name>
    <investigator_title>Chief, Division of Population Sciences</investigator_title>
  </responsible_party>
  <keyword>cancer</keyword>
  <keyword>palliative</keyword>
  <keyword>chemotherapy</keyword>
  <keyword>metastatic</keyword>
  <keyword>colorectal</keyword>
  <keyword>communication</keyword>
  <keyword>informed consent</keyword>
  <keyword>video</keyword>
  <keyword>education</keyword>
  <keyword>oncology</keyword>
  <keyword>patient-centered</keyword>
  <keyword>outcomes research</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Colorectal Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>If interested in obtaining data from this project, please contact PI Deb Schrag at deb_schrag@dfci.harvard.edu.</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
